MicroRNAs in osteoporosis: current evidence and clinical perspectives
Rheumatology · 10.07.2026 · 64 (4) · 338-344
DOI: 10.5114/reum/220000 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology, online erschienen am 10.07.2026. Verfasst von Marta Świecka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, University Clinical Centre, Medical University of Gdansk, Poland. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Osteoporosis, a widespread skeletal disorder, is defined by low bone mineral density and elevated fracture risk. Although dual-energy X-ray absorptiometry is the diagnostic standard, its limitations drive the search for novel biomarkers. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression at the post-transcriptional level, play important roles in bone remodelling and the pathogenesis of osteoporosis. They influence cell differentiation, proliferation, and apoptosis, and their dysregulation contributes to bone metabolism disorders. MiR-133a promotes osteoclastogenesis and inhibits osteogenesis, while miR-214-3p suppresses osteogenesis by targeting factors such as osterix. MiR-125b is upregulated in osteoporosis, negatively affecting osteogenic markers, and miR-21-5p shows complex, context-dependent effects on bone cells. Emerging candidates include miR-483-5p, miR-497-5p, and miR-422. These molecules provide insight into osteoporosis mechanisms and hold potential as diagnostic and therapeutic targets. Although miRNA-based therapies are promising, further studies are required to validate the findings and improve delivery strategies. Advances in miRNA research may enable earlier diagnosis and more effective osteoporosis treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, University Clinical Centre, Medical University of Gdansk, Poland.
ORCID-Profile: Marta Świecka, Michał Chmielewski
Zitieren
APA
Świecka, M., & Chmielewski, M. (2026). MicroRNAs in osteoporosis: current evidence and clinical perspectives. Rheumatology, 64(4), 338-344. https://doi.org/10.5114/reum/220000
Vancouver
Świecka M, Chmielewski M. MicroRNAs in osteoporosis: current evidence and clinical perspectives. Rheumatology. 2026;64(4):338-344. doi:10.5114/reum/220000
BibTeX
@article{wiecka2026,
author = {Świecka, Marta and Chmielewski, Michał},
title = {MicroRNAs in osteoporosis: current evidence and clinical perspectives},
journal = {Rheumatology},
year = {2026},
volume = {64},
number = {4},
pages = {338--344},
doi = {10.5114/reum/220000}
}
EUVIMED